1. Scrip
  2. >>Business

Wugen Raises $172m To Advance NK Cells In Blood Cancers, Solid Tumors

Lead Program Being Tested In AML, Moving Into Other Cancers

 
• By Mandy Jackson

Wugen has worked on its platform in stealth mode while co-founders at Washington University in St. Louis tested initial product WU-NK-101 in AML. Its new funding will support company-sponsored trials. 

business team working on financial data analysis
Wugen raised $36m in seed and series A funding as it worked toward its $172m series B round • Source: Alamy

Wugen Inc. has raised nearly $200m to date to fund its natural killer (NK) cell and chimeric antigen receptor T-cell (CAR-T) therapies, including a $172m series B venture capital round announced on 15 July to advance and expand its clinical trial programs. The company believes that its platform for developing memory NK cells will improve upon the efficacy demonstrated with non-memory NK cell therapies, with a similar safety profile that has reduced toxicity compared with CAR-T therapies.

CEO Dan Kemp, who joined Wugen earlier this year from Takeda Pharmaceutical Co. Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business